United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $480.85, for a total value of $4,568,075.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $156,008,416.55. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Down 0.8%

Shares of NASDAQ:UTHR traded down $4.07 during midday trading on Tuesday, reaching $481.47. 414,645 shares of the company traded hands, compared to its average volume of 517,124. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35. The firm has a market capitalization of $20.65 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 2.38 and a beta of 0.56. The firm’s fifty day moving average price is $509.98 and its two-hundred day moving average price is $539.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 EPS. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp grew its holdings in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the second quarter valued at approximately $30,000. Caitlin John LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $37,000. International Assets Investment Management LLC lifted its position in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new stake in United Therapeutics during the second quarter valued at approximately $81,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on UTHR shares. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Finally, Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $621.00.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.